ClinicalTrials.gg
RecruitingNCT07237607Updated Apr 15, 2026

Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders

An interventional study of "Exp-ED" Digital Exposure-Therapy Chatbot app in Eating Disorders, Anorexia Nervosa and Bulimia Nervosa, sponsored by Milton S. Hershey Medical Center. Recruiting at 1 site in United States. Open to participants aged 12 Years to 26 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
12 Years to 26 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 259 studies in Feeding and Eating Disorders with a site in United States — 35 open to participants now, 49 under way, none of them phase 3. Feeding and Eating Disorders · United States.

Planned enrollment
172nd of 215
20 · median 66
Started
2026
with 13 others
No phase
169 of 259
28 open now
Primary completion
2027-06
later than 25 of 48 live
Registered
243rd of 259
by date

Among the 259 studies in Feeding and Eating Disorders with a site in United States, this one is the 172nd largest by planned enrollment of the 215 interventional ones that give a count, is one of 14 that started in 2026, is one of 169 with no phase, reaches primary completion later than 25 of the 48 other live ones, and was the 243rd registered.

Feeding and Eating Disorders

645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.

Browse Feeding and Eating Disorders studies →

Open to participants now

35 of the 259 studies in Feeding and Eating Disorders with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.

This study: 12 Years to 26 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 259 studies in Feeding and Eating Disorders with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to develop and refine an artificial intelligence (AI)-powered Exposure Therapy for Eating Disorders chatbot web-app that effectively engages adolescents and young adults and decreases anxiety about weight gain. Participants will use the web-app as a supplemental therapeutic tool during their first six weeks of treatment in a Partial Hospitalization Program. Participants will complete assessments every two weeks, including: (1) semi-structured interviews about their experience with the chatbot web-app; (2) implementation outcome measures (e.g., feasibility, usability, acceptability); and (3) anxiety about weight gain.

Read the detailed description

The overarching goal of this study is to develop and refine an AI-powered Exposure Therapy for Eating Disorders (Exp-ED) chatbot app that effectively engages adolescents and young adults (AYAs) with eating disorders (EDs) and decreases anxiety about weight gain. The investigators will enroll 20 AYAs (ages 12-26 years) entering the Partial Hospitalization Program (PHP) for EDs at the Penn State Milton S. Hershey Medical Center. The initial version of the Exp-ED chatbot app will be developed by an interdisciplinary team with expertise in exposure therapy for EDs (Dr. Essayli), AI (Dr. Nawab), and implementation science (Dr. Lenker). Participants will use the Exp-ED chatbot app as a supplemental therapeutic tool during their first six weeks of PHP treatment. Participants will complete assessments every two weeks, including: (1) semi-structured interviews about their experience with the Exp-ED chatbot app, including design issues and engagement barriers; (2) implementation outcome measures (e.g., feasibility, usability, acceptability); and (3) anxiety about weight gain. Success will be evaluated using pre-determined benchmarks derived from previous mental health chatbot research. This project has two aims:

Aim 1: Iteratively adapt an exposure therapy chatbot app for AYAs with EDs. The investigators will conduct monthly reviews of mixed-methods data and use the Framework for Reporting Adaptations and Modifications-Enhanced (FRAME) to systematically document and evaluate modifications to the chatbot app. Each revised version will be tested with new participants, creating an iterative development process that continues throughout the project period. All adaptation decisions and their empirical foundations will be documented to create a comprehensive record of the app's development via implementation science frameworks.

Aim 2. Evaluate the feasibility, usability, acceptability, and preliminary efficacy of the Exp-ED chatbot app. H2.1: The investigators will recruit ≥50% of eligible AYAs with EDs. H2.2: Over the six-week project period, participants will use the app ≥18 times. H2.3: Participants will engage with the chatbot for ≥100 minutes total. H2.4: Participants will rate the Exp-ED chatbot app as acceptable (score ≥68 on the System Usability Scale). H2.5: Participants will report a ≥50% reduction in anxiety about weight gain.

03

Conditions studied

  • Eating Disorders
  • Anorexia Nervosa
  • Bulimia Nervosa
  • Binge-Eating Disorder
04

Who can participate

Ages eligible
12 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age is between or equal to 12-26 years
  • Admitted to the Penn State Health Eating Disorder Partial Hospital Program (PHP) or Intensive Outpatient Program (IOP)
  • Have a personal smartphone
  • Have a diagnosis of anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), or other specified feeding or eating disorder (OSFED)
  • Be English speaking

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of avoidant/restrictive food intake disorder (ARFID)
  • Have acute suicidality
  • Diagnosis of an intellectual disability
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    "Exp-ED" Digital Exposure-Therapy Chatbot app

    Exp-ED will target anxiety about weight gain through an exposure based treatment.

    Behavioral: "Exp-ED" Digital Exposure-Therapy Chatbot app

Interventions

  • Behavioral"Exp-ED" Digital Exposure-Therapy Chatbot app

    Exp-ED is a text-based digital health application designed for smartphones and personal computers. It provides exposure-based content to adolescents and young adults with eating disorders. The chatbot guides users through exposure exercises (structured steps to reduce anxiety over time), records subjective distress ratings (self-reported anxiety scores), and offers evidence-based coping prompts. These sessions are intended to supplement clinical care during a six-week partial hospitalization program.

06

What researchers measure

Primary outcomes

  1. Number of times participants use web-app.

    The investigators will measure the number of times participants use the web-app

    Time frame: End of Week 2, End of Week 4, End-of-Treatment (Week 6)

  2. Number of minutes participants engage with the web-app.

    The investigators will measure the number of minutes participants engage with the web-app

    Time frame: End of Week 2, End of Week 4, End-of-Treatment (Week 6)

  3. Percent of eligible Adolescents and Young Adults Consented

    The investigators will measure the percent of eligible adolescents and young adults who consent to the study.

    Time frame: Through study completion, an average of 1 year

  4. System Usability Scale Survey (SUS)

    The System Usability Scale Survey (SUS) is a 10-item self-report questionnaire that examines the participant's attitude towards the web-app. Scores range from 10-50, with higher scores indicating a better overall experience with the app.

    Time frame: End of Week 2, End of Week 4, End-of-Treatment (Week 6)

  5. Weight Gain Anxiety Questionnaire

    The Weight Gain Anxiety Questionnaire is a 12-item self-report questionnaire that targets anxiety about weight gain. The scores are measured on a 0-100 scale, with the higher the score indicating more distress about weight gain, with the exception for question 12 which is reverse scored.

    Time frame: Baseline, End of Week 2, End of Week 4, End-of-Treatment (Week 6)

Secondary outcomes

  1. Clinical Impairment Assessment (CIA)

    The Clinical Impairment Assessment Questionnaire (CIA) is a 16-item self-report measure of the severity of psychosocial impairment due to eating disorder features and focuses on the past 28 days. The 16 items cover impairment in domains of life that are typically affected by eating disorder psychopathology: mood and self-perception, cognitive functioning, interpersonal functioning, and work performance. The responses are scored 0,1,2 and 3, with a higher rating indicating a higher level of impairment. The total range is between 0 and 48.

    Time frame: Baseline, End-of-Treatment (Week 6)

  2. Eating Disorder Examination - Self-Report Questionnaire (EDE-Q)

    The Eating Disorder Examination Questionnaire (EDE-Q) is a 28-item self-report questionnaire. It was designed to assess the range, frequency, and severity of behaviors associated with a diagnosis of an eating disorder. A global score is obtained by summing the four subscales scores (ranging from 0-6) and dividing the total by the number of subscales (4). The score of items are calculated and range from 0 to 6. The higher score indicate greater ED symptoms.

    Time frame: Baseline, End-of-Treatment (Week 6)

  3. Eating Disorder Fear Questionnaire (EDFQ)

    The Eating Disorder Fear Questionnaire (EDFQ) is a 20-item self-report questionnaire. It examines the participant's severity of behaviors associated with a diagnosis of an eating disorder. The response range between 1 to 7 with a total range of 20 to 140. The higher rating indicates a higher severe impairment.

    Time frame: Baseline, End-of-Treatment (Week 6)

  4. Fear of Food Measure (FOFM)

    The Fear of Food Measure (FORM) is a 23-item self-report questionnaire. It examines the participant's severity of behaviors associated with a diagnosis of an eating disorder. Each item is scored on a 1-7 scale. The questionnaire range from 23 to 161 meaning 23: no fear of food and 161 meaning severe fear of food.

    Time frame: Baseline, End-of-Treatment (Week 6)

  5. Generalized Anxiety Disorder-7 (GAD-7)

    The Generalized Anxiety Disorder-7 is a 7-item self-report questionnaire that targets anxiety symptoms. The scores range from 0 to 21, with higher scores indicating higher levels of anxiety.

    Time frame: Baseline, End-of-Treatment (Week 6)

  6. Patient Health Questionnaire-9 (PHQ-9)

    The Patient Health Questionnaire-9 is a 9-item self-report questionnaire that targets depressive symptoms. The scores range from 0-27, with higher scores indicating a higher level of depression.

    Time frame: Baseline, End-of-Treatment (Week 6)

  7. Eating Anxiety Questionnaire

    The Eating Gain Anxiety Questionnaire is a 14-item self-report questionnaire that targets anxiety about eating fear foods. The scores are measured on a 0-100 scale, with the higher the score indicating more distress about eating fear foods, with the exception for question 12 which is reverse scored.

    Time frame: Baseline, End of Week 2, End of Week 4, End-of-Treatment (Week 6)

Other outcomes

  1. Columbia Suicide Severity Rating Scale (CSSRS)

    Evidence-based metric evaluating for presence of suicidal ideation and severity. Scores range from 1 (low risk) to 3 (high risk).

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

Of 267 non-industry interventional studies with no phase under Feeding and Eating Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 15 months is below that.

Counting every sponsor, half of 272 studies reached it within 28 months; a quarter within 14 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 20, 2025
StartActual
Mar 23, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07237607
Responsible party
Jamal Essayli (Assistant Professor, Milton S. Hershey Medical Center) — Principal investigator
First posted
Nov 20, 2025
Start date
Mar 23, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Jamal H Essayli, PhD
Contact
jessayli@pennstatehealth.psu.edu
(717) 531-0003 ext. 320191

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion